NPC(SH:600713)2014-04-04 16:00Financial Performance - The company's operating revenue for 2013 was ¥18,737,790,381.04, representing a 3.96% increase compared to ¥18,024,220,367.66 in 2012[24] - The net profit attributable to shareholders of the listed company reached ¥38,680,653.10, a significant increase of 257.48% from ¥10,820,432.52 in the previous year[24] - The basic earnings per share for 2013 was ¥0.056, up 250.00% from ¥0.016 in 2012[24] - The weighted average return on net assets increased to 3.84% in 2013, up 2.72 percentage points from 1.12% in 2012[24] - The company's expense ratio decreased from 7.35% in 2012 to 5.99% in 2013, indicating better cost management[32] - The company's operating costs increased to CNY 17,543,502,612.19, up 5.30% from CNY 16,660,839,247.10 in the previous year[44] - The total sales revenue for the company in 2013 reached approximately RMB 1,378,083,880.52, representing a growth of 7.65% compared to the previous year[104] Cash Flow and Assets - The company reported a cash flow from operating activities of -¥354,268,278.86, a decrease of 310.66% compared to ¥168,168,397.28 in 2012[24] - The net cash flow from operating activities decreased significantly to CNY -354,268,278.86, a decline of 310.66% compared to CNY 168,168,397.28 in the previous year[44][48] - The company achieved a net cash flow from investment activities of CNY 162,963,813.72, a turnaround from a negative cash flow of CNY -179,357,147.53 in the previous year[44][48] - The company's total assets at the end of 2013 were ¥9,649,665,958.88, reflecting a 4.58% increase from ¥9,227,049,026.33 at the end of 2012[24] - The company's current assets totaled CNY 8,250,934,901.79, compared to CNY 7,777,031,012.53 at the start of the year, reflecting a year-over-year increase[197] - Cash and cash equivalents decreased to CNY 1,456,543,285.16 from CNY 1,938,214,334.46, showing a decline in liquidity[197] Strategic Initiatives - The company made substantial progress in the strategic cooperation project with Alliance Healthcare, receiving approval from the Ministry of Commerce for the investment[33] - The company successfully divested from 13 subsidiaries and completed share repurchases to enhance its core business focus, achieving a business concentration rate of over 95%[34] - The company expanded its medical institution services, establishing partnerships with 5 key hospitals in Nanjing and achieving significant growth in prescription handling[35] - The company is the first in Jiangsu Province to develop third-party logistics for pharmaceuticals, with ongoing logistics center projects expected to complete in 2014[38] - The company is focusing on expanding its retail business in the Jiangsu, Anhui, and Fujian markets to increase market share and maximize operating profits in a low-margin environment[74] Corporate Governance and Compliance - The company has implemented measures to address the regulatory findings and improve compliance with securities laws[124] - The company faced regulatory scrutiny, receiving a corrective order from the Jiangsu Securities Regulatory Bureau on April 28, 2013, due to information disclosure violations[122] - Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission for failing to disclose information as required[123] - The company has established a risk control framework, supervising investment and asset management to mitigate operational risks[173] - The company has revised its governance structure to comply with legal standards and improve operational transparency[176] Shareholder and Equity Information - The total number of shares outstanding is 693,580,680, with 100% being tradable shares[131] - The company’s controlling shareholder, Nanjing Pharmaceutical Group, held 145,657,368 shares, representing 21.00% of total shares[139] - The company completed the listing of all restricted shares on May 22, 2013, allowing for full circulation of shares[132] - The company has a diverse range of business operations, including state-owned asset management and the production and sales of chemical raw materials and formulations[142] - The largest shareholder of Nanjing Pharmaceutical Group holds 21.00% of the company's shares, ensuring independent operations and financial accountability[171] Social Responsibility - The company actively fulfilled its social responsibility during public health emergencies, ensuring the supply of medicines and sending over RMB 5 million worth of medical supplies to disaster areas[83] - The company has been recognized for its social responsibility efforts, receiving multiple awards including the "Best Social Responsibility Listed Company" title[83] Employee and Management Information - The company employed a total of 4,154 staff, including 156 in the parent company and 3,998 in major subsidiaries[162] - The company has a total of 1,005 retired employees that incur expenses[162] - The company emphasizes a competitive compensation management policy that aligns with job responsibilities and performance assessments[163] - The board of directors appointed Liang Yutang as the president on January 17, 2014, following his resignation from previous roles[156] - The company has established a performance management culture that promotes the alignment of interests among shareholders, employees, and other stakeholders[163]